Rapamycin inhibits both motility through down-regulation of p-STAT3 (S727) by disrupting the mTORC2 assembly and peritoneal dissemination in sarcomatoid cholangiocarcinoma

Sun Mi Hong, Chang Wook Park, Hyung Jin Cha, Jung Hee Kwon, Young Sung Yun, Nam Gyu Lee, Dae Ghon Kim, Hong Gil Nam, Kwan Yong Choi

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Cholangiocarcinoma (CC) is a malignant epithelium neoplasm that originates from the bile epithelium and for which there are few therapeutic strategies. The mTOR pathway involved in many cellular processes was reported to be up-regulated in various cancers. We investigated the activation of the AKT/mTOR pathway in CC cell lines with different degrees of dedifferentiation and found that rapamycin could suppress the motility and the peritoneal dissemination of sarcomatoid SCK cells. Inhibition of the mTOR pathway with rapamycin decreased significantly the number of tumor nodules and prolonged the survival rates of nude mice inoculated with sarcomatoid CC cells. Prolonged treatments with rapamycin were found to disrupt the mTORC2 assembly and to reduce the phosphorylation of STAT3 at Ser 727. Rapamycin decreased both mRNA and protein levels of MMP2 and Twist1, which are regulated by STAT3 and associated with cancer metastasis. The overexpression of STAT3 S727A lacking the phosphorylation site resulted in significantly less sensitivity to rapamycin than the overexpression of STAT3 WT. Taken together, our results suggest that rapamycin could suppress the motility of sarcomatoid CC by down-regulating p-STAT3 (S727) through the impairment of mTORC2 assembly.

Original languageEnglish (US)
Pages (from-to)177-187
Number of pages11
JournalClinical and Experimental Metastasis
Volume30
Issue number2
DOIs
StatePublished - Feb 1 2013

Keywords

  • Motility
  • Peritoneal dissemination
  • Rapamycin
  • STAT3
  • Sarcomatoid cholangiocarcinoma
  • mTOR pathway
  • mTORC2 assembly

Fingerprint Dive into the research topics of 'Rapamycin inhibits both motility through down-regulation of p-STAT3 (S727) by disrupting the mTORC2 assembly and peritoneal dissemination in sarcomatoid cholangiocarcinoma'. Together they form a unique fingerprint.

  • Cite this